By Genetic Engineering & Biotechnology News –
Researchers at the University of California San Diego (UCSD) have found that two of the most frequently administered stem cell therapies, which are often used interchangeably, actually contain completely different types of cells. For their studies the team analyzed cell populations of autologous bone marrow aspirate concentrate (BMAC) and adipose-derived stromal vascular fraction (ADSVF) collected from the same subjects. Their results, they suggest, challenge the current “one-cell-cures-all” paradigm in orthopedic stem cell therapeutics and highlight the need for more informed and rigorous characterization of injectable stem cell therapies before they are marketed for use in patients.
